These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15072606

  • 1. Does finasteride alter the pathology of the prostate and cancer grading?
    Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R.
    Clin Prostate Cancer; 2004 Mar; 2(4):228-35. PubMed ID: 15072606
    [Abstract] [Full Text] [Related]

  • 2. [Is tumour grade applicable to finasteride-treated prostate cancer?].
    Molinié V, Ruffion A, Allory Y, Leroy X, Cochand Priollet B, Paraf F, de la Taille A.
    Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
    Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI.
    Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
    [Abstract] [Full Text] [Related]

  • 8. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
    Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL.
    Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA.
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [Abstract] [Full Text] [Related]

  • 13. Androgen deprivation therapy for precancerous lesions of the prostate.
    Hull D, Bostwick DG.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG.
    Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.